Bio-Reference Laboratories Inc
Bio-Reference Laboratories — Merger or Acquisition (June 2015)
15 slides from Bio-Reference Laboratories's merger presentation, Jun 10, 2015

Slide 1: Investor Presentation June 2015
Investor Presentation June 2015

Slide 2: Important Information for Investors and Shareholders
Important Information for Investors and Shareholders This communication does not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities or a solicitation of any vote or approval. This communication relates to a proposed business combination between Bio - Ref

Slide 3: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward - Looking Statements Certain statements in this communication regarding the proposed acquisition of Bio - Reference Laboratories by OPKO, including any statements regarding the expected timetable for completing the proposed transaction, synergies, benefits and

Slide 4: Transaction Overview
Transaction Overview On June 3, 2015, OPKO Health, Inc. (NYSE: OPK) and Bio - Reference Laboratories, Inc. (NASDAQ: BRLI) announced that the companies have signed a definitive merger agreement under which OPKO will acquire Bio - Reference Laboratories Terms BRLI shareholders will receive 2.75 sh

Slide 5: Bio-Reference is a Unique Clinical Lab Asset
Bio-Reference is a Unique Clinical Lab Asset 0 Demonstrated strong, consistent organic growth - 21 years of -20% compound annual revenue growth 0 Created and expanded franchises in multiple specialty markets including oncology, women's health and genetics in lab testing and healthcare provider commu

Slide 6: Transaction Rationale
Transaction Rationale 5 Near - term Longer - term Leverage BRLI’s channels to accelerate the adoption of OPKO’s diagnostic products Utilization of genomic data for personalized therapy 1 2

Slide 7: Transaction Rationale: Near-term
Transaction Rationale: Near - term Extensive phlebotomy draw stations offer synergistic opportunity for efficient commercialization of 4Kscore test for high - grade prostate cancer ~175 BRLI patient service centers located throughout the United States for collection of patient specimens Levera

Slide 8: Transaction Rationale: Longer-term
Transaction Rationale: Longer - term 7 Utilization of genomic data for personalized therapy 2 BRLI’s vast array of genetics and genomics data should benefit OPKO in its drug discovery and clinical trial programs GeneDx was the first commercial laboratory to offer next generation sequencing for p

Slide 9: OPKO – a High Growth Medical Products Company with a Diversified Portfolio
Diagnostics 4Kscore ® blood test for aggressive prostate cancer risk Claros ® 1 immunoassay system for rapid, lab quality in - office testing Pharmaceuticals Vitamin D therapeutics for Secondary Hyperparathyroidism (SHPT) Platform technology to make peptides and proteins long - acting to tre

Slide 10: The 4Kscore Test as a Minimally Invasive Alternative to Prostate Biopsy
The 4Kscore Test as a Minimally Invasive Alternative to Prostate Biopsy Clinical utility is based on three decades of clinical biomarker research and over 20,000 men tested in Europe and the US Identifies the actual risk of aggressive prostate cancer for the individual patient High grade prost

Slide 11: The 4Kscore Test Outperforms PSA and Other Prostate Cancer Tests on the Market
The 4Kscore Test Outperforms PSA and Other Prostate Cancer Tests on the Market 10 Sensitivity 4Kscore® AUC = 0.82 1 AUC = area under the curve Larger AUC = better accuracy for predicting aggressive prostate cancer PSA AUC = 0.69 1 AUC of other tests when applied to aggressive disease PHI = 0.70, 0.6

Slide 12: Leverage BRLI National Reach to Accelerate Diagnostic Products Commercialization
11 Leverage BRLI National Reach to Accelerate Diagnostic Products Commercialization

Slide 13: Shared Resources and Unique Specialty Capabilities
Shared Resources : infrastructure and senior management, scientific expertise and clinical acumen Unique Specialty Capabilities : market (product) specific expertise, specialized clinical connection and applications and focused product managers and mark eti ng materials Each Specialty Sales unit sha

Slide 14: GeneDx Accumulates Deep Insights in Genetic Information
GeneDx Accumulates Deep Insights in Genetic Information 13 Establish a genomics partnership that will focus on all sequencing based genetic testing, including but not limited to the following key disease states: Prenatal (Non - Invasive pre - natal testing, Next - generation carrier screening)

Slide 15: Transaction Offers OPKO Operating Flexibility
Transaction Offers OPKO Operating Flexibility 14 $47 $97 $91 $629 $729 $851 $676 $825 $942 2012 2013 2014 Historical and Pro forma Revenue ($ mm) BRLI generated $88mm operating income in calendar year 2014 * Addition of projected BRLI cash flow would make OPKO cash flow positive Commercial inf
Source: SEC EDGAR · 425 filed Jun 10, 2015


